Contineum Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | — | $0.0 | $50.0 | — |
| Operating income | -$68.1 | -$50.9 | $16.1 | — |
| Net income | -$60.0 | -$42.3 | $22.7 | — |
| Cash Flow Statement | ||||
| Free cash flow | -$55.5 | -$33.4 | $18.9 | — |
| Share repurchases | — | $0.0 | $<0.1 | — |
Shares outstanding 37.6M · Free float 85.9%
Annual filing data through FY ended December 31, 2025; float as of October 5, 2026.